Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.

ABSTRACT:

Background

Linaclotide, a guanylate cyclase C agonist relieves irritable bowel syndrome with predominant constipation (IBS-C) symptoms, but how it improves pain in humans is unknown.

Aims

To investigate the effects of linaclotide and placebo on the afferent and efferent gut-brain-gut signalling in IBS-C patients, in a randomised clinical trial.

Methods

Patients with IBS-C (Rome III) and rectal hypersensitivity were randomised (2:1) to receive linaclotide (290 µg) or placebo for 10 weeks and undergo bi-directional gut and brain axis assessment using anorectal electrical stimulations and transcranial/transspinal-anorectal magnetic stimulations. Rectal sensations were examined by balloon distention. Assessments included abdominal pain, bowel symptoms and quality of life

SUBMITTER: Rao SSC 

PROVIDER: S-EPMC7384154 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature